Connor Clark & Lunn Investment Management Ltd. reduced its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 36.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,825 shares of the biopharmaceutical company’s stock after selling 1,625 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Regeneron Pharmaceuticals were worth $1,055,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of REGN. Diversified Trust Co raised its position in Regeneron Pharmaceuticals by 0.8% in the 4th quarter. Diversified Trust Co now owns 3,630 shares of the biopharmaceutical company’s stock valued at $1,356,000 after buying an additional 30 shares during the last quarter. Whittier Trust Co. raised its position in Regeneron Pharmaceuticals by 195.7% in the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 45 shares during the last quarter. AdvisorNet Financial Inc raised its position in Regeneron Pharmaceuticals by 208.0% in the 4th quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 52 shares during the last quarter. Scotia Capital Inc. raised its position in Regeneron Pharmaceuticals by 7.5% in the 4th quarter. Scotia Capital Inc. now owns 814 shares of the biopharmaceutical company’s stock valued at $304,000 after buying an additional 57 shares during the last quarter. Finally, Advisor Group Inc. raised its position in Regeneron Pharmaceuticals by 1.9% in the 4th quarter. Advisor Group Inc. now owns 3,397 shares of the biopharmaceutical company’s stock valued at $1,269,000 after buying an additional 62 shares during the last quarter. Institutional investors own 66.87% of the company’s stock.

Shares of Regeneron Pharmaceuticals stock opened at $414.47 on Friday. Regeneron Pharmaceuticals Inc has a 1 year low of $281.89 and a 1 year high of $442.00. The firm has a market cap of $45.29 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 1.68 and a beta of 1.20. The company has a quick ratio of 3.67, a current ratio of 4.47 and a debt-to-equity ratio of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share for the quarter, topping the consensus estimate of $5.10 by $1.74. The company had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.73 billion. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.23 EPS. Equities analysts expect that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current fiscal year.

A number of equities research analysts recently commented on the company. BidaskClub lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Piper Jaffray Companies increased their price target on Regeneron Pharmaceuticals to $487.00 and gave the company an “overweight” rating in a research report on Tuesday, February 26th. Guggenheim lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $466.00 to $425.00 in a research report on Friday, February 22nd. Zacks Investment Research lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. Finally, Oppenheimer increased their price target on Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the company an “outperform” rating in a research report on Thursday, February 7th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus price target of $413.76.

In other news, Director Joseph L. Goldstein sold 1,791 shares of the stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $410.00, for a total transaction of $734,310.00. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $5,786,740. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Sanofi sold 131,115 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The disclosure for this sale can be found here. Insiders have sold a total of 134,754 shares of company stock valued at $55,439,356 in the last quarter. 12.42% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This story was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2019/03/17/connor-clark-lunn-investment-management-ltd-sells-1625-shares-of-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: What is Put Option Volume?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.